Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens

Cytomegalovirus reactivation is frequent in multiple myeloma patients treated with daratumumab‐based regimens

Abstract Background Viral reactivations are frequent in hematologial patients due to their cancer‐related and drug‐induced immunosuppressive status. Daratumumab, an anti‐CD38 monoclonal antibody, is used for multiple myeloma (MM) treatment, and causes immunosuppression by targeting CD38‐expressing n...

Full description

Bibliographic Details
Main Authors: Danilo De Novellis, Raffaele Fontana, Bianca Serio, Emilia Vaccaro, Roberto Guariglia, Denise Morini, Michela Rizzo, Valentina Giudice, Carmine Selleri
Format: Article
Language:English
Published: Wiley 2024-07-01
Series:Cancer Medicine
Subjects:
cytomegalovirus reactivation
daratumumab
infectious disease
multiple myeloma
Online Access:https://doi.org/10.1002/cam4.7402

Internet

https://doi.org/10.1002/cam4.7402

Similar Items